» Articles » PMID: 25986923

EMT, CTCs and CSCs in Tumor Relapse and Drug-resistance

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 May 20
PMID 25986923
Citations 282
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor relapse and metastasis are the primary causes of poor survival rates in patients with advanced cancer despite successful resection or chemotherapeutic treatment. A primary cause of relapse and metastasis is the persistence of cancer stem cells (CSCs), which are highly resistant to chemotherapy. Although highly efficacious drugs suppressing several subpopulations of CSCs in various tissue-specific cancers are available, recurrence is still common in patients. To find more suitable therapy for relapse, the mechanisms underlying metastasis and drug-resistance associated with relapse-initiating CSCs need to be identified. Recent studies in circulating tumor cells (CTCs) of some cancer patients manifest phenotypes of both CSCs and epithelial-mesenchymal transition (EMT). These patients are unresponsive to standard chemotherapies and have low progression free survival, suggesting that EMT-positive CTCs are related to co-occur with or transform into relapse-initiating CSCs. Furthermore, EMT programming in cancer cells enables in the remodeling of extracellular matrix to break the dormancy of relapse-initiating CSCs. In this review, we extensively discuss the association of the EMT program with CTCs and CSCs to characterize a subpopulation of patients prone to relapses. Identifying the mechanisms by which EMT-transformed CTCs and CSCs initiate relapse could facilitate the development of new or enhanced personalized therapeutic regimens.

Citing Articles

Human papillomavirus, vaginal microbiota and metagenomics: the interplay between development and progression of cervical cancer.

Leon-Gomez P, Romero V Front Microbiol. 2025; 15:1515258.

PMID: 39911706 PMC: 11794528. DOI: 10.3389/fmicb.2024.1515258.


Exploring COX-Independent Pathways: A Novel Approach for Meloxicam and Other NSAIDs in Cancer and Cardiovascular Disease Treatment.

Cheng L, Hu Z, Gu J, Li Q, Liu J, Liu M Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598398 PMC: 11597362. DOI: 10.3390/ph17111488.


Intricate relationship between cancer stemness, metastasis, and drug resistance.

Dakal T, Bhushan R, Xu C, Gadi B, Cameotra S, Yadav V MedComm (2020). 2024; 5(10):e710.

PMID: 39309691 PMC: 11416093. DOI: 10.1002/mco2.710.


Novel Isolating Approaches to Circulating Tumor Cell Enrichment Based on Microfluidics: A Review.

Qiao Z, Teng X, Liu A, Yang W Micromachines (Basel). 2024; 15(6).

PMID: 38930676 PMC: 11206030. DOI: 10.3390/mi15060706.


GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications.

Du Y, Zhao J J Hepatocell Carcinoma. 2024; 11:1171-1183.

PMID: 38911292 PMC: 11193986. DOI: 10.2147/JHC.S471239.


References
1.
Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

2.
Gomez-Cabrero A, Wrasidlo W, Reisfeld R . IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model. PLoS One. 2013; 8(8):e73607. PMC: 3754963. DOI: 10.1371/journal.pone.0073607. View

3.
Goodgame B, Viswanathan A, Zoole J, Gao F, Miller C, Subramanian J . Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol. 2009; 4(11):1370-4. DOI: 10.1097/JTO.0b013e3181b6bc1b. View

4.
Gelderblom H, Jinks R, Sydes M, Bramwell V, Van Glabbeke M, Grimer R . Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 2011; 47(6):895-902. DOI: 10.1016/j.ejca.2010.11.036. View

5.
Alves C, Fonseca A, Muys B, de Barros E Lima Bueno R, Burger M, de Souza J . Brief report: The lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells. 2013; 31(12):2827-32. DOI: 10.1002/stem.1547. View